# Core Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/core-medical

- Industry: Medical Devices & Equipment
- Headquarters: Shenzhen, China
- Website: www.coretechmed.com
- Total disclosed funding: $75M
- Latest round: Series D (Apr 24, 2025)
- Investors on record: 15

## About

Established in 2016 and based in Shenzhen, China, Core Medical operates as a medical device products developer that mainly provides mechanical circulatory support solutions and related products. The company cooperates with Guangdong Provincial People's Hospital, Nanjing First Hospital, and Second Xiangya Hospital of Central South University, etc. It has GMP-compliant 10,000-grade production workshops, engineering, and biomedical laboratories. In July 2022, it acquired ISO13485 medical device quality management system. As of 2024, it has applied for nearly 350 domestic and foreign patents. In April 2025, Core Medical closed over USD 100 million of series D funding co-led by new investors Legend Capital and Aramco Ventures and returning investors Loyal Valley Capital and CoStone Capital. The company provides mechanical circulatory support solutions and related products for patients with heart failure. Its product includes Corheart 6 implantable left ventricular assist system. It is an implantable blood circulation support system and can treat end-stage heart failure in miniature. The company's technology platform includes fluid mechanics simulation and testing platform, motor simulation and testing platform, and blood compatibility testing platform. The company generates revenue by providing mechanical circulatory support solutions and related products. The company will use the series D funding to develop innovative products and advance its international strategic layout.

## Funding rounds

- Series D, Apr 24, 2025 — Legend Capital, New Alliance Capital, Aramco Ventures, CoStone Capital, Delian Capital, Loyal Valley Capital
- Series C, Apr 17, 2023, $29M — Greenwoods Asset Management, Loyal Valley Capital
- Series C, Dec 30, 2022 — New Alliance Capital, CoStone Capital, Shenzhen Salubris Pharmaceuticals, GL Ventures, Hangzhou Yuanhenglizhen Equity Investment Management, Nanshan SEI Investment
- Series B, May 19, 2021, $31M — China International Capital Corporation, New Alliance Capital, Puhua Capital, GL Ventures
- Series A, Oct 16, 2020, $15M — New Alliance Capital, Puhua Capital, Efung Capital
- Angel, Nov 27, 2019 — Lotus Lake Capital

## Investors

- Lotus Lake Capital (https://capitalatlas.ai/funds/lotus-lake-capital) — Angel
- New Alliance Capital (https://capitalatlas.ai/funds/new-alliance-capital) — Series A, Series B, Series C, Series D
- Puhua Capital (https://capitalatlas.ai/funds/puhua-capital) — Series A, Series B
- Efung Capital (https://capitalatlas.ai/funds/efung-capital) — Series A
- China International Capital Corporation (https://capitalatlas.ai/funds/china-international-capital-corporation) — Series B
- GL Ventures (https://capitalatlas.ai/funds/gl-ventures) — Series B, Series C
- CoStone Capital (https://capitalatlas.ai/funds/costone-capital) — Series C, Series D
- Shenzhen Salubris Pharmaceuticals — Series C
- Hangzhou Yuanhenglizhen Equity Investment Management — Series C
- Nanshan SEI Investment (https://capitalatlas.ai/funds/nanshan-sei-investment) — Series C
- Greenwoods Asset Management (https://capitalatlas.ai/funds/greenwoods-asset-management) — Series C
- Loyal Valley Capital (https://capitalatlas.ai/funds/loyal-valley-capital) — Series C, Series D
- Legend Capital — Series D
- Aramco Ventures (https://capitalatlas.ai/funds/aramco-ventures) — Series D
- Delian Capital (https://capitalatlas.ai/funds/delian-capital) — Series D